ASH 2024 Rilzabrutinib safe and effective in ITP
- 09-12-2024
- Thrombocytopenia
- News
MedNet.nl: The oral Bruton tyrosine kinase inhibitor rilzabrutinib demonstrated a strong therapeutic effect with a favorable safety profile in patients with immune thrombocytopenia (ITP) in the phase 3 LUNA 3 trial.